To elucidate the specific mechanism through which NAP1L1 affects BIRC2, HCC cells were treated with actinomycin ketone (CHX), proteasome inhibitor MG132, lysosomal inhibitors chloroquine and 3-methyladenine (3-MA). Here, NAP1L1 is linked to hepatocellular carcinoma.